Silence Therapeutics plc
SLN$738M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaLONDON116 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Sep 15, 2026
26wMarket Overview
Stock performance and key metrics
SLN News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
SLN124
Polycythemia Vera
SLN360
Cardiovascular Diseases
Atu027 & gemcitabine in lead in safety period
Carcinoma, Pancreatic Ductal
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SLN124 | Phase 2 | Polycythemia Vera | - | - |
SLN360 | Phase 2 | Cardiovascular Diseases | - | - |
Atu027 & gemcitabine in lead in safety period | Phase 2 | Carcinoma, Pancreatic Ductal | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply